Our experience with antidepressant treatment
in the obese and type 2 diabetics
by
Svacina S.
Third Medical Department,
First Faculty of Medicine,
Charles University, Prague,
Czech Republic.
stepan.svacina@lf1.cuni.cz
Prague Med Rep. 2005;106(3):291-6.

ABSTRACT

We established depressive symptoms prevalence in 100 patients recommended to our obesity clinic and we started antidepressant treatment in 41 of them. It has been noted that administration of SSRI leads to weight reduction after 6 months, but is followed by a weight increase later. Our experience shows that 12 months long administration of bupropion and tianeptine leads to continuous weight loss. Antidepressant administration leads to an increase in pharmacotherapy adherence, which is significantly higher than in diet and psychotherapy alone. In diabetics, antidepressants reduce glucose levels, too. Their influence on weight and diabetes compensation is, however, smaller than in "classic" anti-obesity drugs, sibutramine and orlistat.

Antidepressant
Neuroplasticity
Asthma prevention
Anxious depression
Tianeptine (Stablon)
Tianeptine: structure
Apoptosis prevention
Bupropion (Wellbutrin)
Dopamine and neuroplasticity
Tianeptine and Panic Disorder
Ethanol withdrawal and tianeptine
Discriminative stimulus properties
Neurobiology of mood, anxiety and emotion

Refs
and further reading

HOME
HedWeb
Nootropics
cocaine.wiki
Future Opioids
BLTC Research
MDMA/Ecstasy
Superhapiness?
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family